Malaria Vaccines for the World September 28 – 30, 2010 Washington DC Kellogg Conference Hotel Gallaudet University http://www.meetingsmanagement.com/mvw_2010/index.htm
Tuesday, Sept 28 Diverse Approaches to Malaria Vaccine Development: “Inducing potent humoral and cellular responses to multiple pre-erythocytic-stage antigens using pDNA.” Dr. David B. Weiner,Professor, Dept. of Pathology & Laboratory Medicine, University of Pennsylvania; Chairman, Scientific Advisory Board, Inovio Pharmaceuticals
AIDS Vaccine 2010 September 28 to Oct. 1 Atlanta, Georgia CNN Center at the Omni Hotel http://www.hivvaccineenterprise.org/conference/2010/index.php
Wednesday, Sept. 29, 10:30am Novel Immunogens and Inserts: “Co-delivery of mucosal chemokine plasmids in systemically administered DNA vaccines elicits systemic and mucosal immune responses in rhesus macaques.” Dr.Michele Kutzler, Drexel University College of Medicine
Wednesday, Sept. 29, 1:30pm Pre-Clinical and Early Clinical Trials: “Enhanced magnitude of immune responses induced by SIV antigens delivered by plasmid DNA via electroporation and boosted by recombinant adenovirus 5.” Dr.Natalie Hutnick, University of Pennsylvania
In addition, Inovio and its collaborators will present five posters showcasing Inovio’s novel DNA vaccine delivery technology and preclinical vaccine results during the AIDS Vaccine 2010 conference.
4th Vaccine and ISV Annual Global Congress October 3 – 5, 2010 Vienna, Austria Hilton Vienna Am Stadtpark http://www.vaccinecongress.com/index.asp
Sunday, Oct. 3, 4:30pm Gene-based and subunit vaccines: “Potent as well as protective immune responses induced by highly engineered DNA vaccines delivered by CELLECTRA® EP in Nonhuman Primates and Humans.” Dr. David B. Weiner, Professor, Dept. of Pathology & Laboratory Medicine, University of Pennsylvania; Chairman, Scientific Advisory Board, Inovio Pharmaceuticals
TBD “VGX-3100: Induction of cellular and humoral responses in post-LEEP CIN 2/3 following immunotherapy with HPV16 & 18 SynCon™ DNA vaccines via electroporation,”.Dr. Niranjan Y. Sardesai, SVP, R&D, Inovio Pharmaceuticals
In addition to the oral presentations, Inovio and its collaborators will present two posters highlighting Inovio’s preliminary pre-clinical vaccine results with target antigens in its research pipeline.
About Inovio Pharmaceuticals, Inc.
Inovio is developing a new generation of vaccines, called DNA vaccines, to treat and prevent cancers and infectious diseases. These SynCon™ vaccines are designed to provide broad cross-strain protection against known as well as newly emergent strains of pathogens such as influenza. These vaccines, in combination with Inovio’s proprietary electroporation delivery devices, have been shown to be safe and generate significant immune responses. Inovio’s clinical programs include HPV/cervical dysplasia and cancer (therapeutic), avian flu (preventive), and HIV vaccines (both preventive and therapeutic). Inovio is developing universal influenza and other vaccines in collaboration with scientists from the University of Pennsylvania. Other partners and collaborators include Merck, National Cancer Institute, HIV Vaccines Trial Network, National Microbiology Laboratory of the Public Health Agency of Canada, and PATH Malaria Vaccine Initiative. More iel/My%20Documents/www.inovio.com">www.inovio.com.
